Opinion Article - Allied Journal of Medical Research (2023) Volume 7, Issue 4

Nanotechnology for precision drug delivery: Advancements in pharmacology and therapeutics

Department of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

*Corresponding Author:

Proykova Bawa
Department of Medical and Health Sciences
University of Auckland, Auckland, New Zealand
E-mail: proykova.b@auckland.ac.nz

Received: 27-Jun-2023, Manuscript No. AAAJMR-23-105804; Editor assigned: 29-Jun-2022, PreQC No. AAAJMR-23-105804(PQ); Reviewed: 13-Jul-2023, QC No. AAAJMR-23-105804; Revised: 17-Jul-2023, Manuscript No. AAAJMR-23-105804(R); Published: 24-Jul-2023, DOI:10.35841/aaajmr-7.4.186

Citation: Bawa P. Nanotechnology for precision drug delivery: Advancements in pharmacology and therapeutics. Allied J Med Res. 2023;7(4):186

Introduction

Precision medicine, which aims to deliver therapies tailored to individual patients, has revolutionized the field of healthcare. Nanotechnology, with its ability to manipulate and control matter at the nanoscale, has emerged as a powerful tool in precision drug delivery. By designing and engineering nanocarriers, researchers can enhance the efficacy, safety, and targeted delivery of therapeutic agents. This article explores the advancements in pharmacology and therapeutics achieved through nanotechnology-enabled precision drug delivery [1].

Nano carriers, such as nanoparticles, liposomes, dendrimers, and micelles, are designed to encapsulate and deliver therapeutic agents to specific target sites in the body. These carriers offer several advantages, including improved drug solubility, protection from degradation, prolonged circulation time, and enhanced cellular uptake. Moreover, their small size allows them to bypass physiological barriers and accumulate in target tissues more efficiently. Nano carriers can be surfacefunctionalized with ligands, antibodies, or peptides to actively target specific cells or tissues. This active targeting facilitates the selective accumulation of drugs at the desired site, reducing off-target effects and enhancing therapeutic efficacy. By exploiting the unique characteristics of tumor tissues, nanocarriers can be designed to accumulate preferentially in cancer cells, resulting in improved anti-cancer drug delivery while minimizing damage to healthy tissues [2].

Nanotechnology enables the design of drug delivery systems with controlled release profiles. Various stimuli-responsive Nano carriers have been developed that can release drugs in response to specific triggers, such as pH, temperature, light, or enzymatic activity. This controlled release mechanism allows for sustained drug release at the target site, optimizing therapeutic efficacy while minimizing systemic toxicity. The human body possesses several biological barriers that can impede drug delivery to target sites. Nanotechnology provides innovative solutions to overcome these barriers. For instance, nanocarriers can be engineered to cross the blood-brain barrier, enabling the delivery of therapeutic agents to the central nervous system for the treatment of neurological disorders. Similarly, Nano carriers can be designed to penetrate mucosal barriers, allowing for efficient drug delivery through oral, nasal, or ocular routes [3].

Nanotechnology has enabled the development of theranostic platforms that integrate both therapeutic and diagnostic capabilities. Theranostics combines targeted drug delivery with real-time imaging and monitoring of treatment response. Nanocarriers can be loaded with contrast agents or imaging probes, allowing for non-invasive imaging modalities such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), or fluorescence imaging. This integration of diagnostics and therapeutics facilitates personalized medicine by providing real-time feedback on treatment efficacy and guiding therapeutic decision-making. The safety and biocompatibility of nanocarriers are of paramount importance for their clinical translation. Extensive research is being conducted to ensure the biocompatibility of nanomaterials, evaluate their long-term effects, and assess potential toxicity. Surface modifications and engineering approaches are employed to reduce immunogenicity and improve the biodegradability of nanocarriers, minimizing adverse effects and optimizing their clinical applicability [4].

Nanotechnology has revolutionized the field of precision drug delivery, providing innovative solutions to overcome challenges associated with conventional drug administration. Through the design and engineering of nanocarriers, researchers have achieved enhanced targeting, controlled release, and improved accumulation of therapeutic agents at specific sites. Nanotechnology-enabled precision drug delivery has the potential to revolutionize pharmacology and therapeutics, enabling personalized medicine, improving treatment outcomes, and reducing adverse effects. Continued research, collaboration, and regulatory efforts are essential to further unlock the vast potential of nanotechnology in the realm of precision drug delivery and advance patient care [5].

References

1. D Mello SR, Cruz CN, Chen ML, et al. The evolving landscape of drug products containing nanomaterials in the United States. Nat Nanotechnol. 2017;12(6):523-9.

Indexed at, Google Scholar, Cross Ref

2. Caster JM, Patel AN, Zhang T, et al. Investigational nanomedicines in 2016: A review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(1):1416.

Indexed at, Google Scholar, Cross Ref

3. Bobo D, Robinson KJ, Islam J, et al. Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373-87.

Indexed at, Google Scholar, Cross Ref

4. Tran S, DeGiovanni PJ, Piel B, et al. Cancer nanomedicine: A review of recent success in drug delivery. Clin Transl Med. 2017;6:1-21.

Indexed at, Google Scholar, Cross Ref

5. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med.2001;10–29.

Indexed at, Google Scholar, Cross Ref